Abstract:Activation of the toll-like receptors 7 and 8 has emerged as a promising strategy for cancer immunotherapy. Herein, we report the design and synthesis of a series of pyrido[3,2-d]pyrimidine-based toll-like receptor 7/8 dual agonists that exhibited potent and near-equivalent agonistic activities toward TLR7 and TLR8. In vitro, compounds 24e and 25a significantly induced the secretion of IFN-α, IFN-γ, TNF-α, IL-1β, IL-12p40, and IP-10 in human peripheral blood mononuclear cell assays. In vivo, compounds 24e, 24m, and 25a significantly suppressed tumor growth in CT26 tumor-bearing mice by remodeling the tumor microenvironment. Additionally, compounds 24e, 24m, and 25a markedly improved the antitumor activity of PD-1/PD-L1 blockade. In particular, compound 24e combined with the anti-PD-L1 antibody led to complete tumor regression. These results demonstrated that TLR7/8 agonists (24e, 24m, and 25a) held great potential as single agents or in combination with PD-1/PD-L1 blockade for cancer immunotherapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00179?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00179</a>.Homology and similarity analysis between TLR7 and 8; agonistic activities of compounds 24e, 25a, and 26a in other homologous TLRs; supplementary multiplexed immunoassays for cytokines; synergy analysis of tumor size and the survival rate; representative flow cytometric analysis of tumor-infiltrating immune cells; detection of absolute counts of tumor-infiltrating immune cells and synergy analysis; relationships between the TVs and the amounts of immune cells; phospholipidosis detection of 24e, 24m, and 25a; synthesis of compounds 16a, 27, and 35; NMR spectra of target compounds; and HPLC traces of compounds 5, 24e, 24k, 24m, 25a, and 34 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_002.csv">CSV</a>)Molecular docking for GS-9620 into TLR7 and molecular docking for 17d, 24e, 24m, and 34, into TLR7 and TLR8 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00179/suppl_file/jm1c00179_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Identification and Immunological Evaluation of Novel TLR2 Agonists Through Structure Optimization of Pam(3)CSK(4)

Synthesis, evaluation and molecular dynamics study of human toll-like receptor 2/6 specific monoacyl lipopeptides as candidate immunostimulants

Identification and immunological evaluation of novel TLR2 agonists through structural optimization of Diprovocim

Structural Characterization of Tlrs with Novel Agonists

Identification of novel and potent synthetic TLR agonists

Design and Immunological Evaluation of a Hybrid Peptide As a Potent TLR2 Agonist by Structure-Based Virtual Screening.

Design, Synthesis, and Structure–Activity Relationship of N -Aryl- N ′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists

Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response.

The Novel Toll-Like Receptor 2 Agonist Sup3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells

Design, Synthesis, and Biological Characterization of Novel PEG-linked Dimeric Modulators for CXCR4.

Targeting The Tlr2 Receptor With A Novel Thymopentin-Derived Peptide Modulates Immune Responses

The Development of a Highly Potent and Selective Human Toll-like Receptor 2 Agonist: Synthesis and Biological Evaluation of CaLGL-1 and Its Derivatives

Design, Synthesis and Biological Evaluation of (2′,5′ and 3′5′-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING)

Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim.

Serine-/Cysteine-Based sp 2 -Iminoglycolipids as Novel TLR4 Agonists: Evaluation of Their Adjuvancy and Immunotherapeutic Properties in a Murine Model of Asthma

Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology

Design, Synthesis and Biological Evaluation of Acridone Analogues As Novel STING Receptor Agonists

Structure‐Based Design and Synthesis of Lipid A Derivatives to Modulate Cytokine Responses